Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Luye Pharma Stops $1 Billion Acquisition of Beijing Jialin

publication date: Jun 3, 2015
Luye Pharma of Shandong Province terminated its $1 billion agreement to buy Beijing Jialin Pharma, without giving any explicit reason for its dramatic change of heart. After Luye concluded its $746 million IPO in Hong last summer, the company struck two separate deals to acquire Jialin soon after. It seemed as though the acquisition was the unspecified purpose behind the IPO. Now, describing itself as "prudent," Luye has abandoned the transaction, implying the expected returns did not justify the risk. More details....

Stock Symbol: (HK: 2186)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital